STAAR Surgical Company (STAA)

Market Cap	1.61B +77.8%
Revenue (ttm)	290.38M +4.0%
Net Income	-21.03M
EPS	-0.42
Shares Out	49.79M
PE Ratio	n/a
Forward PE	43.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,071,810
Open	31.95
Previous Close	32.07
Day's Range	31.16 - 32.60
52-Week Range	15.59 - 35.87
Beta	1.20
Analysts	Buy
Price Target	29.67 (-8.17%)
Earnings Date	May 13, 2026

About STAA

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 921
• Stock Exchange: NASDAQ
• Ticker Symbol: STAA
• Website: https://www.staar.com

Financial Performance

In fiscal year 2025, STAAR Surgical Company's revenue was $239.44 million, a decrease of -23.72% compared to the previous year's $313.90 million. Losses were -$80.45 million, 298.1% more than in 2024.

Analyst Summary

According to 11 analysts, the average rating for STAA stock is "Buy." The 12-month stock price target is $29.67, which is a decrease of -8.17% from the latest price.

Price Target

$29.67

(-8.17% downside)

Analyst Consensus: Buy